×
Innoviva SG&A Expenses 2010-2024 | INVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Innoviva sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Innoviva SG&A Expenses 2010-2024 | INVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Innoviva sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Eli Lilly (LLY)
$763.3B
Novo Nordisk (NVO)
$377.1B
Johnson & Johnson (JNJ)
$363.9B
AbbVie (ABBV)
$309.7B
Merck (MRK)
$248.6B
Roche Holding AG (RHHBY)
$247.8B
AstraZeneca (AZN)
$217.9B
Novartis AG (NVS)
$210.4B
Pfizer (PFE)
$150.9B
Sanofi (SNY)
$132.3B
Bayer (BAYRY)
$22.2B